Valbiotis presents baseline data from the INSIGHT study at the European Society of Hypertension (ESH) Congress, the leading community for healthcare professionals involved in the management of hypertension, which will take place from May 31 to June 3, 2024 in Berlin. This presentation will detail the protocol as well as the baseline characteristics of the population recruited in this multicenter, randomized, double-blind placebo-controlled study. It mainly aims to evaluate the effectiveness of TOTUM•854, a mixture of 6 plant extracts, on the reduction of blood pressure in people with moderate elevation of blood pressure. A total of 410 individuals were included in the study spread across 3 countries. As expected, this population is characterized by a significant proportion of subjects presenting metabolic disorders also linked to overweight and obesity. The recruited population is well suited for the study objectives and results are expected in the coming months.
See the poster